ARS Pharmaceuticals Inc.
SPRY | NASDAQ
$4.35
+$0.24 (+5.84%)
At close: Sep 21, 2026, 4:00 PM ET
$4.35
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 84.28M | 89.15M | 30K | 1.32M | 5.51M | 17.84M |
Cost of Revenue | 20.42M | 20.56M | n/a | 17.12M | 213K | 14.07M |
Gross Profit | 63.86M | 68.59M | 30K | -15.8M | 5.29M | 3.77M |
Operating Income | -179.45M | -3.08M | -67.52M | -35.52M | -19.45M | -469K |
Interest Income | 10.67M | n/a | n/a | n/a | 800K | 400K |
Pretax Income | -171.38M | 8.29M | -54.37M | -34.68M | -20.24M | -1.07M |
Net Income | -171.3M | 8M | -54.37M | -34.68M | -20.24M | -1.07M |
Selling & General & Admin | 230.12M | n/a | 47.28M | 18.66M | 4.69M | 4.23M |
Research & Development | 13.18M | 19.58M | 20.27M | 18.38M | 20.27M | 14.07M |
Other Expenses | n/a | 52.1M | n/a | -17.32M | -213K | -14.07M |
Operating Expenses | 243.3M | 71.68M | 67.55M | 19.71M | 24.75M | 4.23M |
Interest Expense | 2.6M | n/a | n/a | n/a | 106K | 29K |
Selling & Marketing Expenses | n/a | n/a | n/a | 200K | n/a | n/a |
Cost & Expenses | 263.73M | 92.23M | 67.55M | 36.83M | 24.96M | 18.3M |
Income Tax Expense | -80K | 288K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 98.57M | 96.94M | 95.22M | 39.96M | 28.87M | 34.7M |
Shares Outstanding (Diluted) | 98.57M | 102.39M | 95.22M | 39.96M | 28.87M | 34.7M |
EPS (Basic) | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 | -0.03 |
EPS (Diluted) | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 | -0.03 |
EBITDA | -167.41M | 8.37M | -54.29M | -34.36M | -19.92M | -463K |
EBIT | -168.78M | 8.29M | -54.37M | -34.68M | -20.14M | -469K |
Depreciation & Amortization | 1.37M | 79K | 73K | 319K | 213K | 6K |
Add to Watchlist
Select watchlists to add or remove SPRY